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A B S T R A C T
Objectives: To explore the impact of applying different non-standardized analytical
choices for quality of life measurement to obtain quality-adjusted life years (QALYs). In
addition to more widely discussed issues such as the choice of instrument (e.g. EQ-5D or
SF-6D?) researchers must also choose between different recall periods, scoring algorithms
and interpolations between points of measurement.
Methods: A prospective survey was made among 114 Belgian patients with acute hepatitis
A illness. Using non-parametric tests and generalized linear models (GLM’s), we compared
four different methods to estimate QALY losses, two based on the EQ-5D (administered
during the period of illness without recall period) and two based on the SF-6D (administered
after illness with 4 weeks recall period).
Results: We found statistically significant differences between all methods, with the non-
parametric SF-6D-based method yielding the highest median QALY impact (0.032 QALYs).
This ismore than five times as high as the EQ-5D-basedmethodwith linear health improve-
ment, which yields the lowest median QALY impact (0.006 QALYs).
Conclusions: Economic evaluations of health care technologies predominantly use QALYs to
quantifyhealthbenefits.Non-standardisedanalyticalchoicescanhaveadecision-changingimpact
on cost-effectiveness results, particularly ifmorbidity takes up a substantial part of the total QALY
loss.Yet thesechoicesare rarely subjected tosensitivityanalysis. Researchersanddecisionmakers
should be aware of the influence of these somewhat arbitrary choices on their results.
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To compare health benefits across different medical treat-
ments the quality-adjusted life year (QALY) has become a
widely used summary health outcome comprising both mor-
bidity and mortality effects. Nevertheless QALYs and cost-
utility analyses continue to be seen by some as a controversial
instrument for policy analysis [1–4]. One reason for criticisms
is that there is no single objective standardised tool to obtain
themorbidity impact of disease and differentmethods appear
to generate different results [5–7]. Amongst the many instru-
ments available to estimate the quality of life (QoL) associated
with living in different health states, the EQ-5D [8] and the
SF-6D [9–11] are both popular multi-attribute classification
systems. These surveys typically generate a single time point
utility value for each relevant health state, which is then used
to value an average patient’s health path. There are several
important steps in this process, all with their specific pitfalls
and problems. The health state of interest should be defined
and described and it should be valued. This is done by asking
questions across several dimensions that are assumed to con-
tribute to enjoying a healthy life. Respondents summarise
their position on the ordinal scale of each dimension. In order
to be a valid measure of health, these dimensions should ex-
haustively cover all relevant dimensions of health-related
QoL. The EQ-5D covers the dimensions of mobility, self care,
usual activities, pain/discomfort and anxiety/depression. The
SF-6D distinguishes between physical functioning, role limi-
tations, social functioning, pain, mental health and vitality.
The choice of respondents (most often patients, health prac-
titioners or the general population) can be of substantial influ-
ence on such valuations [12]. In this article we consider the
patient to be the most appropriate judge of his/her health ex-
perience. Ideally a survey, which asks for the patient’s current
health state, should be taken repeatedly during the period of
illness, in order to estimate the loss in health related QoL.
However, a day-to-day evaluation of a sufficiently large pa-
tient group is usually impractical. A common approach is
therefore to have a survey filled in once (ormultiple times) and
consequently to assume a linear change between the QoL at
the measurement point(s) and perfect health [13]. An alterna-
tivemethod consists ofmeasuring patients’ health status dur-
ing a specified recall period. Bothmethods aim to estimate the
same health path and it is therefore important to establish to
which extent this is the case, and whether the choice for one
of these methods introduces an additional source of uncer-
tainty in economic evaluation.
We aimed to explore the effects of different methods for es-
timating the impact of an acute illness on the QoL valued by
patients. Figure 1 illustrates five different methods to calculate
the QoL impact for a patient experiencing 4 weeks of illness.
Three of thesemethods are based on a current state health sur-
vey such as the EQ-5D and two are based on a survey with a
specified recall period such as the SF-6D. At T1 patients were
surveyed regarding their health state. Their health path is con-
sequently estimated using either of the following assumptions:
the patient has a constant QoL for the duration of the illness,
there is a linear improvement in QoL, or the marginal improve- rment in QoL increases every day (an exponential health im-
provement). The alternative for these interpolations is to ask the
patient after recovering, at T2, to recall his/her health state over
he entire disease episode. In Figure 1 these different methods
yield the following contingent health burden: the rectangle
ABDE for a constant health state, the triangle ABE for a linear
health improvement and the area between the points ABEH for
an exponential change. Assuming that respondents value their
health state between time T1 and T2, at “F”, their retrospective
ealth loss is illustrated as the rectangle ABCF in Figure 1. This
ectangle can be obtainedwith two different scoring algorithms.
In this studywe empirically investigatewhether these con-
eptually different methods lead to significantly different
ALY loss estimates. To test this we focused on hepatitis A,
hich—in contrast to hepatitis B or hepatitis C—can only give
ise to acute disease. Hepatitis A affects the liver, and may
ause mild to severe illness (exceptionally leading to fulmi-
ant hepatitis and death) for on average 2 to 4 weeks [14–16].
e compared the QALY loss estimates of patients resulting
rom four different but conceptually defensible measurement
ethods. Two methods are based on the EQ-5D (taken during
heir illness, without a recall period): one with a linear health
mprovement and one with a constant health state during the
eriod of illness. We will not discuss the exponential method
ince the resultswould always fall between the other twometh-
ds. The other twomethods are based on the SF-6D (taken after
llness, with a recall period of 4weeks): one using the commonly
sed parametric scoring algorithm [9] and one using the more
Fig. 1 – Graphical representation of the different health
measurement methods for a patient experiencing 4 weeks
of illness. The X-axis represents the duration of illness and
the Y-axis the health utility score. The health burden for
the EQ-5D is taken at T1 and estimated by the area
between ABDE for a constant health state, the triangle ABE
for a linear health improvement and ABEH for an
exponential change. The SF-6D is taken at T2 and the
estimated health burden is the rectangle ABCF (for both
scoring algorithms).ecent non-parametric scoring algorithm [17,18].
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Data
Hepatitis A is a notifiable disease in Belgium, implying that phy-
siciansand laboratories should communicate informationabout
new hepatitis A patients to the health inspection services.
Three interlinked surveys were administered prospectively
to all hepatitis A patients aboutwhomnotificationwas provided
to the Flemish public health services from February 1, 2008 to
January 31, 2009. First, the EQ-5D, including a visual analogue
scale (VAS), was sent to the patient immediately after notifica-
tion of illness (approximately 1 week after the first symptoms
appeared) and requested thepatient tovaluehis/herhealthstate
at that time. The SF-12 was sent to the same patients approxi-
mately 3 weeks later, and patients were asked to describe their
health state during the preceding 4 weeks. A third survey was
administered immediately after the SF-12, in order to collect in-
formation on the number of days of symptomatic illness the
patient had experienced from the hepatitis A episode as well as
on the nature of the symptoms experienced, and health care
consumption associated with the period of illness [19]. All three
surveys were linked to an individual patient by a unique anony-
mous code.
QALY calculation
The SF-12 cannot be directly translated into an utility score,
but Brazier et al. [9] reduced the number of questions, creating
a shorter survey (the SF-6D) that can be used for calculating
QALYs. Utility scores from the EQ-5D and the SF-6D were cal-
culated using respectively the UK York time trade-off (TTO)
algorithm [20] and the UK Sheffield standard gamble (SG) al-
gorithm (we use both the parametric [9] and the non-paramet-
ric [17] versions of the latter).
To transform these incomparable utilities into compara-
ble QALY loss estimates, a time dimension needs to be in-
troduced. Assuming that the utility weight associated with
non-affected health states in these patients corresponds to
a value of 1, the parametric SF-6D utility score, representing
the patient’s health during the entire month of illness, can
be transformed into QALY loss estimates as follows:
QALYloss SF-6D  1 
SF-6D score  11
12
The QALY loss from the same SF-6D-survey but with use of
the more recent non-parametric method is calculated in a
similar manner but uses the algorithm described by Khar-
roubi et al. [21].
QALYloss SF-6DNP  1 
SF-6DNP score  11
12
The terms SF-6D and SF-6DNP will be used to refer to the QALY
loss resulting fromusing theparametric and thenon-parametric
scoring algorithm for the SF-6D-survey, respectively.
To calculate QALYs from the EQ-5D we need to make an
assumption about the evolution of the patient’s health ex-
perience. In this study we only consider a constant and a clinear progression (referred to as EQ-5DConstant and EQ-
5DLinear respectively hereafter), and potential alternative
improvements in adverse health experience (e.g., exponen-
tial) are not explored.
QALYloss EQ-5DConstant

days of illness 1  EQ5DScore
365
QALYloss EQ-5DLinear

1
2
days of illness 1  EQ5DScore
365
Figure 1 shows a graphical representation of the intuitive
meaning of these equations, with 1  EQ5DScore being rep-
resented by the line AE and
Days of illness
365
being repre-
sented by T2  T1.
Analyses
The responses from the survey were analysed using SPSS 15.0
(Chicago, Illinois), R 2.8.1,@Risk (Ithaca,NewYork), andMSExcel
2003 (Redmond, WA) software. Missing data were excluded list
wise.We tested the potential bias for excluding data by calculat-
ing the correlation between the VAS score and the number of
questionsansweredand found this tobe insignificant (P0.362).
Summary statistics of the variables obtained in the survey were
produced. The QALY loss predicted by the EQ-5D and the SF-6D
was compared using a paired Wilcoxon signed rank test. The
QALY loss estimated by the SF-6Dwas regressed onto that of the
EQ-5D to enable analysis of the relationship between these two
measures. The natural logarithm of the ratio of the QALY loss
predicted by the SF-6D and the EQ-5D was taken to further in-
vestigate the difference in these measures. A linear regression
model was used to determine and compare the significant ex-
planatory variables that affect the QALY loss predicted by the
EQ-5D and the SF-6D. The sensitivity of the QALY loss mea-
sures with respect to the explanatory variables was com-
pared using a generalized linear model (GLM) with interac-
tion term [22]. This approach is similar to that followed by
Kontodimopoulos et al.[5] Relationships between the five
dimensions of the EQ-5D and the six dimensions of the
SF-6D were analysed with Kendall’s tau rank correlation
coefficient. A 95% level of confidence was used.
Results
The total sample size was 161. Of the entire sample 111 pa-
tients completed the number of days of illness and all ques-
tions on the EQ-5D, both necessary to obtain a valid QALY loss
estimate from the EQ-5D. The SF-6D surveywas filled in by 114
respondents. For 96 patients we were able to obtain a valid
QALY-estimate for both surveys. Table I shows the sample
haracteristics of the discrete variables.
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Table II provides summary statistics of the continuous vari-
bles in the sample, which includes the QALY loss estimates
rom the four measurement methods. Due to the asymmetric
ature of the EQ-5D and SF-6D measures, the median QALY
oss values offer the best basis for comparison between these
wo instruments. The SF-6D basedmethod resulted inmedian
ALY loss values that were more than twice that of the EQ-
DConstant and nearly five times that of the EQ-5DLinear.
he SF-6DNP yielded median values more than five times
hose of the EQ-5DLinear and more than 2.5 times those
f the EQ-5DConstant. The standard deviations indicate
hat the range of health outcomes is smaller for the SF-6D-
ased method than for the EQ-5D-based methods. The dif-
erence in spread and location can be seen from the descrip-
ive statistics in Table II. As suggested by Kharoubi et al.
17], the differences between outcomes from the SF-6D and
F-6DNP were small. The comparisons between the EQ-5D
nd the SF-6D survey are consequently similar for both al-
orithms. Therefore we focus mainly on the parametric
F-6D score and expand our results with the non-paramet-
ic method where necessary.
Non-parametric tests indicate a statistical difference be-
ween the median QALY loss predicted by the EQ-5DLinear
nd the SF-6D (P  0.0001). Similarly, there is a significant
Table 1 – Sample characteristics.
Percent (n)
Gender
Male 52.2% (72)
Female 47.8% (66)
Education
Primary education 18.6% (24)
Secondary education 41.1% (53)
Tertiary education 27.9% (36)
Other education 12.4% (16)
Working status
Student or child 38.5% (50)
Full-time & part-time employed 50.8% (66)
Unemployed 6.2% (8)
Other employment 4.6% (6)
Table 2 – Descriptive statistics.
Number of valid
responses
Mean
Age 138 27.71
VAS score 127 66.31
No. of symptoms 161 5.60
Days of illness 133 17.82
EQ-5DConstant QALY loss 111 2.55  102
EQ-5DLinear QALY loss 111 1.28  102
SF-6D QALY loss 114 2.80  102
SF-6DNP QALY loss 114 3.00  102
Note: These statistics were obtained for all respondents who indicat
illness and symptoms can be attributed to an asymptomatic patient.
tests of family members of an infected patient. This is also part of th
QALY, quality-adjusted life year; VAS, visual analogue scale.difference between the median QALY loss predicted by the
EQ-5DConstant and the SF-6D (P  0.001). Also, the EQ-5D-
Constant, the EQ-5DLinear and the SF-6D outcomes are all
significantly different from the SF-6DNP (P  0.0001 for all
comparisons). A scatter plot of the coupled health surveys,
shown in Figure 2, compares the outcomes of the QALY loss
measures for the EQ-5DConstant and the SF-6D. Theoretically,
all observations on the scatter plot should be on the 45° refer-
ence line if the two QALY measures produce the same QALY
loss estimates. This is rarely the case. In linewith other studies,
the EQ-5D ismore responsive for patients with apparentlymore
severe illness, but relatively insensitive for patients in milder
disease states,whereas the SF-6D is also sensitive for apparently
milder illness [10]. Patients,who indicated greater disease sever-
ity on the EQ-5D, tend to have a lower score on the SF-6D. Pa-
tientswith lowerQALY losson theEQ-5Dtend togeneratehigher
health burdens on the SF-6D. A number of patients who indi-
cated no health impact on the EQ-5D during the first week of
illness indicated an adverse health impact on the SF-6D. The
EQ-5DLinear by definition results in half the QALY loss com-
pared to the EQ-5DConstant and consequently only results in a
higher QALY loss than the SF-6D in patientswho indicate severe
levels of adverse health impact on the EQ-5D. The QALY loss
estimated by the SF-6DNP is not shown on Figure 2 since its
relationship is similar to that of the EQ-5D and the SF-6D. We
found a linear relationship between SF-6D and SF-6DNP with
greater values of QALY loss for the SF-6DNP as shown inTable II.
We fitted the QALY loss resulting from the SF-6D as a func-
tion of the EQ-5D. The best fit was a third order polynomial
(adjusted R2  0.343) and is also shown in Figure 2. The esti-
mated regression equation is as follows:
SF-6Dˆ 0.02 0.685 EQ5DConstant  7.057EQ-5DConstant2
 17.413EQ-5DConstant3 (1)
he regression line between the EQ-5DLinear and the SF-6D
as a similar shape to that of the EQ-5DConstant and the
F-6D. The turning point for the EQ-5DConstant is 0.063 and
or the EQ-5DLinear it is 0.032. Therefore it is estimated that
he SF-6D-based method is an increasing function of the
Q-5DConstant if EQ-5DConstant  0.063 and decreasing
therwise (we ignore the second turning point since it is
Median Min Max Standard deviation
25.50 0 74 17.192
67.00 20 100 19.765
6.00 0 11 3.12
14.00 0 65 12.32
1.22  102 0 1.73  101 3.33  102
6.10  103 0 8.65  102 1.67  102
2.98  102 0 4.68  102 1.08  102
3.27  102 0 4.66  102 1.02  102
response to the specific question. The minimum number of days of
are also notified to the health inspection services through laboratory
ical image of hepatitis A virus and, therefore, should be included.ed a
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286 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 8 2 – 2 9 0outside the range of the EQ-5DConstant). We found similar
results for the SF-6DNP estimate. The quadratic equation
was the best fit with an adjusted R2 of 0.369 and the esti-
ated curve had the same turning point.
The differences between the EQ-5D and SF-6D QALY loss
stimates were further investigated by calculating the ratio
f the natural logarithm of the EQ-5D and SF-6D QALY loss
stimates. A cluster emerged for respondents that indicated
erfect health on the EQ-5D and imperfect health on the
F-6D. This clustering was confirmed by a two-step cluster
nalysis. The same cluster emerged for the SF-6DNP.
Figure 3 summarizes the distribution of the responses on
he different pairs of similar health-dimensions on both in-
Fig. 2 – Fitted third order polynomial estimating the QALY lo
are observations, red line is third order polynomial fitted to
reference line at the turning point of the polynomial.
Fig. 3 – (A) Comparison of dimensions for patients indicating
indicating severest level of problems.truments [23]. The EQ-5D dimensions reflect the health ex-
erience as it is measured during the illness (usually at the
tart). The SF-6D dimensions reflect how the illness was expe-
ienced in retrospect, 4 weeks after onset of illness. Patients
ndicate more intermediate levels of health problems on the
F-6D survey, especially on the dimensions ‘role limitations’
nd ‘anxiety/depression’ (80% vs. 20%). The ‘vitality’ di-
ension is lacking on the EQ-5D but is shown to be an impor-
ant aspect of hepatitis A illness on the SF-6D survey. The
ercentage of respondents indicating themost severe levels of
roblems also differs between the surveys. Fifty-one percent
ndicated most severe problems with ‘role limitations’ on the
F-6D vs. 5% in the EQ-5D. ‘Usual activities’ was a stronger
sulting from the SF-6D as a function of the EQ-5D. Dots
ata, blue line is the 45° reference line, and green line is
problem. (B) Comparison of dimensions for patientsss re
the dany
287V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 8 2 – 2 9 0contributor to the patients health state on the EQ-5D than
‘social functioning’ on the SF-6D.
The relationship between the dimensions of the EQ-5D
and the SF-6D survey were analysed using Kendall’s tau
rank correlation coefficient. This indicated that all of the
dimensions are correlated to each other with the exception
of ‘pain/discomfort’ and ‘self-care’ (P  0.197), ‘vitality’ and
‘anxiety/depression’ (P  0.074); and ‘social functioning’ and
‘self-care’ (P  0.057) being uncorrelated.
Significant predictors of QALY loss
Amultiple regression model indicated that the VAS score and
number of symptoms were significant predictors of the QALY
loss estimated by the EQ-5D and the SF-6D. Multicollinearity
in these linear models was not significant despite a degree of
correlation (Pearson correlation coefficient  0.2) between
VAS and the number of symptoms. The cost of treatment,
number of days of illness (only tested for the SF-6D), gender,
smoking status, previous experience with serious illness, and
age of the patient were found to be non-significant.
As can be expected, there is a negative relationship be-
tween the VAS score and theQALY loss for both the EQ-5D and
the SF-6D. Both QALY loss measures indicated a positive rela-
tionship with the number of symptoms. The same results
were obtained for the SF-6DNP as for the SF-6D.
The sensitivity of the QALY lossmeasures to the VAS score
and the number of symptoms was analysed by fitting two
Fig. 4 – Regression lines of the EQ-5DConstant, EQ-5DLinear
EQ-5DConstant; green line, EQ-5DLinear; red line, SF-6D; bla
SF-6DNP (VAS score = 4.95); B, ED-5DLinear and SF-6D (VAS
D, EQ-5DConstant and SF-6D (VAS score = 46.11).GLMs. The GLMs had the QALY loss estimates as dependentvariable and an intercept and three dummy variables for the
four possible QALY loss estimators. Furthermore, the first
model had three interaction terms for theQALYmeasures and
the VAS score, and the second model had three interaction
terms for the QALYmeasures and the number of symptoms. A
significant coefficient for an interaction term indicates a
threshold for the VAS/number of symptoms such that below
this threshold, the QALY loss estimated by one of themethods
will be greater than that of the othermethods and an opposite
relationship above the threshold.
The interaction between the VAS score and the QALY loss
measure was significant (P  0.001 for EQ-5DLinear*VAS; P 
0.001 for SF-6D*VAS; P  0.001 for SF-6DNP*VAS), but not be-
tween theVAS score and the number of symptoms (P 0.123 for
EQ-5DLinear*Number of symptoms; P 0.140 for SF-6D*Number
of symptoms; P 0.098 for SF-6DNP*Number of symptoms). This
suggests the existence of a threshold for VAS. Below this thresh-
old theQALY loss estimated by the EQ-5D is greater compared to
the one based on the SF-6D, and vice versa above the threshold.
Four linear regression equations were fitted to explore the rela-
tionship between the QALY loss estimates as predicted by the
three measures and the VAS score. These regression lines are
shown in Figure 4, which indicates that for some VAS scores
the QALY loss estimates as predicted by the EQ-5DConstant are
larger than those of the SF-6DandSF-6DNP, and similarly for the
EQ-5DLinear. The threshold between EQ-5DLinear and SF-6D is
estimated at 7.17 and at 46.11 between EQ-5DConstant and SF-
6D. Therefore, it is estimated that for patients with a VAS score
SF-6D onto visual analogue scale (VAS). Blue line,
ne, SF-6DNP. Intersection points: A, EQ-5DLinear and
e = 7.17); C, EQ-5DConstant and SF-6DNP (VAS score 43.35);and
ck li
scorless than 7.17, a greater QALY loss will be predicted by the EQ-
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288 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 8 2 – 2 9 05DLinear than by the SF-6D, but for VAS scores greater than
7.17 the QALY loss estimates from the SF-6D will be greater
than those of the EQ-5DLinear. A similar conclusion can be
made for the threshold between the EQ5DConstant and the
SF-6DNP. The thresholds between the EQ5DLinear and the
SF-6DNP and between the EQ5DConstant and the SF-6DNP
are 4.95 and 43.35, respectively. It is estimated that such
thresholds do not exist for the number of symptoms due to
the insignificant interaction between the QALY loss mea-
sure and the number of symptoms.
Comparison of QALY loss as predicted by the SF-6D with
parametric and non-parametric scoring algorithm
Figure 5 shows thedifference inQALY lossobtainedwith the two
coring algorithms for the SF-6D in hepatitis A patients. In our
ample the utility values ranged [0.439; 1] in the SF-6D and
0.4406; 1] in the SF-6DNP. This does not allowus to compare the
oorest health states in the entire spectrum of possible health
tates on the SF-6D survey since the lowest possible utility is
.257 and 0.203, respectively. On the opposite side of the scale,
ith the best health states, we found higher QALY loss in the
on-parametric method. For average health states the results
eem to be more equally distributed.
Discussion
We compared the QALY loss estimates produced by measure-
mentmethods based on the EQ-5D and the SF-6D bymeans of
Fig. 5 – Difference of the resulting QALY loss with the param
algorithm for the responses to the SF-6D survey.an interlinked survey from hepatitis A patients in Belgium.The four different health valuation methods produced signif-
icantly (P 0.05) different results. Expressed as amedian from
the population sample, the SF-6D generated QALY losses that
were about two to five times those obtained with the EQ-5D,
assuming a constant QALY loss or a linear improvement in
QALY loss over the illness period, respectively. All methods
were able to identify groups of patients with a different health
state according to criteria with a known relationship to
health-related QoL such as the VAS and the number of symp-
toms. Both surveys yielded higher values of QALY loss for pa-
tients with an apparently more severe form of illness, thus
supporting their validity. However, the magnitude of the dif-
ference between severely ill and mildly ill patients differed
between the instruments. The EQ-5D resulted in higher values
of QALY loss than the SF-6D for patients with more severe
illness (as indicated by a low VAS score and a relatively high
QALY loss on both surveys). The SF-6D generated greater
QALY losses for the majority of patients with only minor or
moderately severe illness. Most patients (93.33%) who indi-
cated no health burden on the EQ-5D indicated a positive ad-
verse impact on the SF-6D. On average the SF-6DNP had a
similar relation to the EQ-5D as the SF-6D but yielded higher
QALY loss. The differences in our sample between the SF-6D
with parametric and with non-parametric scoring algorithm
are consistent with the finding of Kharroubi et al. [17] who
state that the parametric method overestimates the utility of
patients in superior health states, thereby resulting in lower
QALY loss estimates than the non-parametric method.
Our study highlights the variety of analytical choices that
underlie QALY-calculations in practice, and indicates the
(SF-6D) and the nonparametric (SF-6DNP) scoringetricmagnitude of differences in outcome they may generate. Be-
d
E
e
h
o
r
l
t
E
n
s
m
a
o
h
h
a
t
b
f
T
i
a
m
s
o
s
S
t
h
o
t
t
i
h
g
a
S
o
fl
s
s
w
s
i
D
n
a
o
s
b
T
o
w
d
t
s
c
r
k
c
p
d
t
b
a
p
h
t
l
t
C
v
s
m
m
i
289V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 8 2 – 2 9 0cause of multiple contributory factors, which are associated
with the choice and use of a particular standard instrument
(i.e. the recall period, the algorithm, and the requirement to
infer many time points from a single one or a small number of
time points), our study design could not quantify the effect of
a single of these associated factors. Future research may esti-
mate the effect of a single factor by creating more subgroups
in which more combinations of these associated factors can
be kept constant.
Nonetheless several explanations can be proposed for the
observed differences between the EQ-5D and the SF-6D sur-
vey. First, there is a difference in recall period. For the SF-6D
survey, patients recall their health state over a 4-week period,
while the EQ-5D survey captures a patient’s current state. For
hepatitis A, with an expected duration of clinical symptoms
during 3 to 4 weeks (and in our sample up to 65 days [median
14 days,mean 17.8 days; proportion of patients ill for1week,
79%), the so-called “acute” version of the SF (with only 1 week
recall period) would not enable us to capture the full disease-
episode for themajority of patients. However, when consider-
ing the course of illness in retrospect, the memory may aver-
age out the experienced extremes to a more constant level
[24]. Since the patients we surveyed were not ill for exactly 4
weeks they had to reconcile in their valuation their period of
ill-health with their period of good health over the total recall
period.
Second, the SF-6D and the EQ-5D surveys also differ in the
coverage of health dimensions and in the number of levels of
severity in each dimension. The SF-6D survey can generate
18,000 health states while the EQ-5D survey distinguishes be-
tween 243 states. Some studies found the SF-6D survey to be
suffering from a ‘floor effect’. Responses on the dimensions of
physical functioning and role limitations have a dispropor-
tionate number of responses at the lowest level for patient
groups with more severe illness [10,23,25]. In our study, the
ifference was only pronounced for ‘role limitations’. The
Q-5D survey however is said to be suffering from a ‘ceiling
ffect’. Other studies reported that patients indicated perfect
ealth (state 11111) on the EQ-5D survey and imperfect health
n the SF-6D survey [23,25]. In our sample 15% of the coupled
esponses indicated perfect health on the EQ-5D and lower
evels on the SF-6D. This refers to the cluster analysis men-
ioned above.
The SF-6D survey has a dimension that is not present in the
Q-5D, vitality, which can be of special significance for an ill-
ess such as hepatitis A. In our sample 95% indicated at least
ome problems with vitality on the SF-6D. Patients with a
ilder form of illness may not suffer from pain, mobility or
nxiety but still score low on the vitality level. More than 50%
f the respondents indicated severe role limitations, while 5%
ad problemswith self-care on the EQ-5D. Role limitations are
owever more severe than self-care and are perhaps more
ppropriate to capture the limiting effects of having an infec-
ious disease on the patient’s behaviour. Infected people may
e capable of performing several duties but be limited in the
ulfilment thereof out of precaution for infection to others.
his effect, if it is considered to be part of health-related QoL,
s possibly better measured by the SF-6D than in the EQ-5D
nd may explain the higher QALY loss for patients with only tild symptoms. Apart from the differing dimensions, the de-
criptive system of the SF-6D allows for more response levels
n each dimension (four to six vs. three). Patients with only
light problems may be more able to indicate these on the
F-6D scale than on the EQ-5D.
A third possible explanation is the scoring algorithm used
o value the described health states. A multidimensional
ealth description needs to be reduced to one dimension in
rder to be useable for economic evaluation. The EQ-5D and
he SF-6D both use different methods to do this; respectively,
he TTO and the SG method. A number of publications have
ndicated that SG generates higher values for more severe
ealth states than TTO. For milder states the TTO seems to
enerate higher values [10,26,27]. These differences in scoring
lgorithm lead to an EQ-5D scale with twice the range of the
F-6D scale: [0.59 to 1.00] vs. [0.25 to 1.00] for the parametric
ne and [0.20 to 1.00] for the non-parametric one. This is re-
ected in the range of the different QALY loss measures as
hown in Table II. The differences between both SF-6D based
coring algorithms remains small compared to the difference
ith the EQ-5D.
Theremaybeseveral reasonswhycost-utilityanalysis is con-
ideredacontroversial instrument forpolicyadvice.Oneof them
s the lack of an unambiguous method for valuing morbidity.
ifferent methods for valuing the health burden of an acute ill-
ess for which only a single time point measurement is avail-
ble, can lead todifferent results. The inclusionof a recall period,
r the assumption of a linearly improving or a constant health
tate, bothareanalytical choiceswithagreat impact if thehealth
urden of the illness is substantially attributable to morbidity.
hemost appropriate method for health description is a matter
f discussion since there is no ‘gold-standard’ to determine
hich measure approximates best the ‘true health state’. Much
epends on the concept of health that policymakerswant to use
o prioritize. For example, is it the better digested memory of a
pecifichealth state (captured in a surveywith recall period) that
ounts, or is it the immediate experience (as captured in a cur-
ent state survey)? Clearly, relying on memory suffers from all
inds of biases [28,29]. The fact that the SF-6D produces more
onsistent outcomes across the sample than the EQ-5Dmay ex-
lainmore on the functioning of thememory than on the actual
isease experience.
Conversely, a current state description requires the analyst
o make assumptions on the further evolution of the illness
etween the different points ofmeasurement, which can have
significant impact on the estimated QALY, if there is no op-
ortunity to administer surveys regularly. Opting for a linear
ealth improvement instead of a constant health state be-
ween two points in time yields, per definition, half the QALY
oss. This leads to an incremental cost-effectiveness ratio of
wice themagnitude (if onlymorbidity QALYs are considered).
onsidering these differences and the advantages and disad-
antages of each method, researchers should therefore con-
ider performing economic evaluations using different esti-
ates of health benefits, and incorporate the range of the
easures bymeans of sensitivity analysis rather than assum-
ng a single utility score.We have provided a conversion equa-
ion between the QALY loss estimated by the EQ-5D and SF-6D
290 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 8 2 – 2 9 0measures in the case of hepatitis A, which may simplify this
process if one of the measures is available.
Conclusion
This studymade clear that four conceptually defensiblemeth-
ods formeasuring the health burden of an acute illness, based
on the EQ-5D and the SF-6D surveys, produce statistically dif-
ferent results. The hypotheses that the methods based on the
EQ-5D lead to better health scores in healthy patients and
worse scores in severely ill patients than methods based on
the SF-6D were confirmed. However, the most appropriate
method remains a matter for further debate. Researchers
should not only choose between surveys but also consider the
effect of the time at which the survey is taken, the length of
the recall period, the assumed disease progression and the
scoring algorithm underlying the resulting outcome. Cost-
utility analyses should make explicit the underlying tech-
niques and assumptions behind a summary health utility
score and if possible expand the results with other measure-
ment methods in a sensitivity analysis.
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